The Asia-Pacific solution gives emerging companies access to Quintiles' data-driven insights
To help emerging biopharmaceutical companies in the Asia Pacific region, achieve their growth aspirations, Quintiles has launched a new solution set. It is tailored to meet the needs of emerging companies in the world's most diverse and dynamic healthcare market.
"Asia-Pacific is poised to become the world's next biopharma powerhouse, not least because of its growing number of emerging companies with promising pipelines. These companies face formidable challenges as they look to expand into markets or therapeutic areas in which they may have limited or no experience," said Dr Ross Horsburgh, senior vice-president and head of Clinical Development, Asia-Pacific, Quintiles.
The Quintiles Asia-Pacific Emerging Biopharma solution includes, dedicated local project leadership based in Asia-Pac with knowledge of local markets, customs and language; Custom-tailored operational models to meet individual customer priorities and use Quintiles' world-class processes and platforms and accelerated patient recruitment through our global network of 25 Prime and >1,200 Partner sites - with seven of those Prime Sites located in Asia-Pacific.
The Asia-Pacific solution gives emerging companies access to Quintiles' data-driven insights; its knowledge of local markets; its in-depth therapeutic and scientific expertise; and its global drug development platform. It further adds to Quintiles' solutions for emerging companies, which includes Novella Clinical, a specialty CRO focused on the needs of small to mid-sized oncology companies and medical device and diagnostic companies.